US6891021B2
(en)
*
|
1993-02-12 |
2005-05-10 |
Board Of Trustees Of The Leland Stanford Junior University |
Regulated apoptosis
|
US6972193B1
(en)
*
|
1993-02-12 |
2005-12-06 |
Board Of Trustees Of Leland Stanford Junior University |
Regulated transcription of targeted genes and other biological events
|
US5859310A
(en)
|
1993-06-14 |
1999-01-12 |
Basf Aktiengesellschaft |
Mice transgenic for a tetracycline-controlled transcriptional activator
|
CA2165162C
(en)
|
1993-06-14 |
2000-05-23 |
Hermann Bujard |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
US5912411A
(en)
*
|
1993-06-14 |
1999-06-15 |
University Of Heidelberg |
Mice transgenic for a tetracycline-inducible transcriptional activator
|
US5866755A
(en)
*
|
1993-06-14 |
1999-02-02 |
Basf Aktiengellschaft |
Animals transgenic for a tetracycline-regulated transcriptional inhibitor
|
US6004941A
(en)
*
|
1993-06-14 |
1999-12-21 |
Basf Aktiengesellschaft |
Methods for regulating gene expression
|
US5888981A
(en)
*
|
1993-06-14 |
1999-03-30 |
Basf Aktiengesellschaft |
Methods for regulating gene expression
|
US5589362A
(en)
*
|
1993-06-14 |
1996-12-31 |
Basf Aktiengesellschaft |
Tetracycline regulated transcriptional modulators with altered DNA binding specificities
|
US5814618A
(en)
*
|
1993-06-14 |
1998-09-29 |
Basf Aktiengesellschaft |
Methods for regulating gene expression
|
US5654168A
(en)
*
|
1994-07-01 |
1997-08-05 |
Basf Aktiengesellschaft |
Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
|
US5789156A
(en)
*
|
1993-06-14 |
1998-08-04 |
Basf Ag |
Tetracycline-regulated transcriptional inhibitors
|
CZ8496A3
(cs)
*
|
1993-07-16 |
1999-06-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Regulovaná apoptóza
|
EP0776335A4
(de)
*
|
1994-08-18 |
1999-09-15 |
Ariad Gene Therapeutics Inc |
Regulierbare elimination der genexpression, genproduktfunktion und gentechnologisch hergestellte wirtszellen
|
US6150527A
(en)
*
|
1994-08-18 |
2000-11-21 |
Ariad Pharmaceuticals, Inc. |
Synthetic multimerizing agents
|
US6133456A
(en)
*
|
1994-08-18 |
2000-10-17 |
Ariad Gene Therapeutics, Inc. |
Synthetic multimerizing agents
|
US20030036654A1
(en)
|
1994-08-18 |
2003-02-20 |
Holt Dennis A. |
Synthetic multimerizing agents
|
CA2197793C
(en)
*
|
1994-08-18 |
2007-04-24 |
Dennis A. Holt |
New multimerizing agents
|
JPH11511643A
(ja)
*
|
1994-10-25 |
1999-10-12 |
ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニア・ユニバーシティ |
遺伝子工学処理された細胞の条件的形質転換
|
GB9425600D0
(en)
*
|
1994-12-19 |
1995-02-15 |
Medical Res Council |
Targeting complexes and use thereof
|
CA2209183A1
(en)
|
1994-12-29 |
1996-07-11 |
Joel L. Pomerantz |
Chimeric dna-binding proteins
|
US6326166B1
(en)
*
|
1995-12-29 |
2001-12-04 |
Massachusetts Institute Of Technology |
Chimeric DNA-binding proteins
|
US5741899A
(en)
*
|
1995-02-02 |
1998-04-21 |
Cell Genesys, Inc. |
Chimeric receptors comprising janus kinase for regulating cellular pro liferation
|
US6103521A
(en)
*
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
US6015665A
(en)
*
|
1995-02-13 |
2000-01-18 |
The Regents Of The University Of Michigan |
Method and composition for regulating apoptosis
|
US7097972B1
(en)
|
1995-02-13 |
2006-08-29 |
Regents Of The University Of Michigan |
Method and composition for regulating apoptosis
|
US6060238A
(en)
*
|
1995-02-13 |
2000-05-09 |
The Regents Of The University Of Michigan |
Method and composition for regulating apoptosis
|
US6747138B1
(en)
|
1995-04-03 |
2004-06-08 |
Regents Of The University Of Michigan |
Methods and compositions for regulating Fas-associated apoptosis
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
WO1996041865A1
(en)
*
|
1995-06-07 |
1996-12-27 |
Ariad Gene Therapeutics, Inc. |
Rapamcycin-based regulation of biological events
|
DE19545351C1
(de)
*
|
1995-12-05 |
1997-07-31 |
Univ Ludwigs Albert |
Eukaryotische Zellen mit Hybridrezeptor und dadurch steuerbarem Genkonstrukt, Verfahren zu deren Herstellung und Verwendung dieser Zellen in der Gentherapie
|
EP0888303B1
(de)
*
|
1996-02-28 |
2010-04-21 |
ARIAD Pharmaceuticals, Inc |
Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen
|
DE69715621T2
(de)
*
|
1996-04-26 |
2003-05-22 |
Massachusetts Inst Technology |
Drei hybriden screening test
|
US6630346B1
(en)
|
1996-06-20 |
2003-10-07 |
Merck & Co., Inc. |
Gene therapy for obesity
|
WO1998026066A1
(en)
*
|
1996-12-09 |
1998-06-18 |
Ariad Gene Therapeutics, Inc. |
Expression of proteins for treating asthma via ligand mediated activation of their encoding genes
|
AU6692298A
(en)
*
|
1997-03-07 |
1998-09-22 |
Ariad Gene Therapeutics, Inc. |
New applications of gene therapy technology
|
US6982082B1
(en)
|
1997-08-27 |
2006-01-03 |
President And Fellows Of Harvard College |
Gene therapy by cell specific targeting
|
US20030220234A1
(en)
*
|
1998-11-02 |
2003-11-27 |
Selvaraj Naicker |
Deuterated cyclosporine analogs and their use as immunodulating agents
|
US6153383A
(en)
|
1997-12-09 |
2000-11-28 |
Verdine; Gregory L. |
Synthetic transcriptional modulators and uses thereof
|
ES2303372T3
(es)
*
|
1998-01-08 |
2008-08-01 |
University Of Washington |
Procedimientos de control de diferenciacion y crecimiento celular que utilizan una proteina de fusion y un farmaco.
|
US6984635B1
(en)
|
1998-02-13 |
2006-01-10 |
Board Of Trustees Of The Leland Stanford Jr. University |
Dimerizing agents, their production and use
|
ES2347027T3
(es)
|
1998-05-22 |
2010-10-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Moleculas bifuncionales y terapias basadas en las mismas.
|
EP1123405A1
(de)
*
|
1998-10-19 |
2001-08-16 |
Ariad Gene Therapeutics, Inc. |
Material und verfahren die konditionale aggreagationsdomänen enthalten
|
WO2000028011A2
(en)
*
|
1998-11-06 |
2000-05-18 |
President And Fellows Of Harvard College |
Fk506-based regulation of biological events
|
US7109317B1
(en)
|
1998-11-06 |
2006-09-19 |
President And Fellows Of Harvard College |
FK506-based regulation of biological events
|
DE19907598A1
(de)
*
|
1999-02-22 |
2000-08-24 |
Schulz Burkhard |
DNA Sequenz kodierend ein FKBP ähnliches Protein, Plasmide, Bakterien, Hefen und Pflanzen enthaltend dieses Protein sowie Mutanten in Arabidopsis für dieses Gen, die in der Ausprägung der Pflanzenarchitektur, der Reaktion gegenüber Brassinosteroiden und ihren Verbindungen und durch Ethylen vermittelten Gravitropismus der Wurzel defekt sind
|
US20030215423A1
(en)
*
|
1999-04-01 |
2003-11-20 |
Merck & Co., Inc. |
Gene therapy for obesity
|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
AU1776501A
(en)
*
|
1999-11-19 |
2001-05-30 |
Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and their use in the disruption of protein-protein interactions
|
US7498025B1
(en)
|
1999-11-19 |
2009-03-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeted bifunctional molecules and therapies based thereon
|
US7220552B1
(en)
|
1999-11-19 |
2007-05-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and their use in the disruption of protein-protein interactions
|
US6887842B1
(en)
|
1999-11-19 |
2005-05-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
|
CA2396062C
(en)
|
1999-12-30 |
2009-11-17 |
President And Fellows Of Harvard College |
Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or t cell subset activity by modulation of xbp-1 activity
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
US7541184B2
(en)
*
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
CA2407872C
(en)
|
2000-05-22 |
2013-11-12 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Receptor-based interaction trap
|
US7323174B1
(en)
|
2000-06-12 |
2008-01-29 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Modulation of immune response and methods based thereon
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
ES2360205T3
(es)
|
2001-03-02 |
2011-06-01 |
Agennix Ag |
Sistema de ensayo de tres híbridos.
|
EP2388590A1
(de)
|
2001-04-02 |
2011-11-23 |
Dana Farber Cancer Institute |
PD-1, ein Rezeptor für B7-4, und Verwendungen dafür
|
GB0112126D0
(en)
|
2001-05-18 |
2001-07-11 |
Allergene Inc |
Composition
|
ES2326040T3
(es)
|
2001-10-19 |
2009-09-29 |
Isotechnika Inc. |
Sintesis de analogos de ciclosporina.
|
EP2308888B1
(de)
|
2001-11-14 |
2017-03-01 |
Janssen Biotech, Inc. |
Anti-IL-6-Antikörper, Zusammensetzungen, Verfahren und Anwendungen
|
US20030144204A1
(en)
*
|
2001-12-19 |
2003-07-31 |
Baylor College Of Medicine |
Akt-based inducible survival switch
|
WO2003062773A1
(en)
*
|
2002-01-24 |
2003-07-31 |
Pei Electronics, Inc. |
Compact integrated infrared scene projector
|
IL162734A0
(en)
|
2002-02-01 |
2005-11-20 |
Ariad Gene Therapeutics Inc |
Phosphorus-containing compounds & uses thereof
|
EP1539929B1
(de)
*
|
2002-06-28 |
2013-04-10 |
Life Technologies Corporation |
Verfahren zur wiederherstellung des immunrepertoirs in patienten mit immunologischen defekten in verbindung mit autoimmunität sowie transplantation von organen oder hämatopoetischen stammzellen
|
WO2004002417A2
(en)
|
2002-06-28 |
2004-01-08 |
Centocor, Inc. |
Mammalian ch1 deleted mimetibodies, compositions, methods and uses
|
US20040175373A1
(en)
*
|
2002-06-28 |
2004-09-09 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
US20050084967A1
(en)
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
US7404950B2
(en)
*
|
2003-02-18 |
2008-07-29 |
Baylor College Of Medicine |
Induced activation in dendritic cell
|
US20050014680A1
(en)
*
|
2003-04-15 |
2005-01-20 |
Crabtree Gerald R. |
Methods and compositions for enhancing neuron growth and survival
|
AU2004239288B2
(en)
|
2003-05-09 |
2010-01-28 |
Centocor, Inc. |
IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
US20050171015A1
(en)
*
|
2003-10-31 |
2005-08-04 |
Crabtree Gerald R. |
Methods and agents for enhancing bone formation or preventing bone loss
|
EP1723239B1
(de)
|
2004-02-09 |
2009-12-09 |
Synamem Corporation |
Verfahren zur erzeugung verankerter proteine
|
MXPA06011425A
(es)
*
|
2004-03-31 |
2007-03-12 |
Johnson & Johnson |
Memiticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.
|
US20050238628A1
(en)
*
|
2004-04-08 |
2005-10-27 |
Blau Carl A |
Methods for treating cancer
|
US7968762B2
(en)
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
US7393662B2
(en)
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
EP1838288A4
(de)
*
|
2004-12-20 |
2010-08-04 |
Ariad Pharma Inc |
Therapeutische stoffe und verfahren
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
HUE042561T2
(hu)
|
2005-06-30 |
2019-07-29 |
Janssen Biotech Inc |
Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
|
DK3219328T3
(da)
|
2005-12-29 |
2020-07-13 |
Janssen Biotech Inc |
Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
|
NZ597557A
(en)
|
2006-03-02 |
2013-10-25 |
Uab Research Foundation |
Mycobacterial disease detection, treatment, and drug discovery
|
CA2648035A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Centocor, Inc. |
Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions or renal disease associated anemia
|
EP2076272B1
(de)
*
|
2006-10-19 |
2015-07-29 |
Baylor College Of Medicine |
Erzeugung einer immunreaktion mittels cd40-induktion sowie strukturerkennungsrezeptoren
|
TW200843794A
(en)
*
|
2006-12-21 |
2008-11-16 |
Centocor Inc |
Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
|
KR20160116056A
(ko)
|
2008-08-14 |
2016-10-06 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
항-il-12/il-23 항체
|
DK2331680T3
(en)
*
|
2008-09-22 |
2017-08-21 |
Baylor College Medicine |
Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters
|
AU2009308935B2
(en)
|
2008-10-31 |
2015-02-26 |
Janssen Biotech, Inc. |
Fibronectin type III domain based scaffold compositions, methods and uses
|
EP2396011B1
(de)
|
2009-02-12 |
2016-04-13 |
Janssen Biotech, Inc. |
Auf fibronectin-typ-iii-domain basierende gerüstzusammensetzungen, verfahren und anwendung
|
EP2258858A1
(de)
|
2009-06-05 |
2010-12-08 |
Universitätsklinikum Freiburg |
Für LSD1 transgenisches Tiermodell für Krebs
|
US9745589B2
(en)
|
2010-01-14 |
2017-08-29 |
Cornell University |
Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
|
SG10201908848RA
(en)
|
2010-03-29 |
2019-10-30 |
Univ Pennsylvania |
Pharmacologically induced transgene ablation system
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
WO2011146862A1
(en)
|
2010-05-21 |
2011-11-24 |
Bellicum Pharmaceuticals, Inc. |
Methods for inducing selective apoptosis
|
EP2582722A4
(de)
|
2010-06-19 |
2013-12-18 |
Sloan Kettering Inst Cancer |
Anti-gd2-antikörper
|
US20130158098A1
(en)
*
|
2010-06-21 |
2013-06-20 |
The Board Of Trustees Of The Leland Standford Junior University |
Alkenyl Substituted Cycloaliphatic Compounds as Chemical Inducers of Proximity
|
WO2012051301A1
(en)
|
2010-10-12 |
2012-04-19 |
President And Fellows Of Harvard College |
Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
|
US9956236B2
(en)
|
2011-02-07 |
2018-05-01 |
Cornell University |
Methods for increasing immune responses using agents that directly bind to and activate IRE-1
|
US20140031418A1
(en)
|
2011-04-20 |
2014-01-30 |
The Trustees Of The University Of Pennsylvania |
Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
|
US10634668B2
(en)
*
|
2012-09-13 |
2020-04-28 |
Takara Bio Usa, Inc. |
Modifiable chemical inducers of proximity and methods of using the same
|
CN110423282B
(zh)
*
|
2013-02-15 |
2023-09-08 |
加利福尼亚大学董事会 |
嵌合抗原受体及其使用方法
|
US20140255403A1
(en)
|
2013-03-06 |
2014-09-11 |
Hadasit Medical Research Services & Development Ltd. |
Oral composition comprising a tnf antagonist and use thereof
|
US9434935B2
(en)
|
2013-03-10 |
2016-09-06 |
Bellicum Pharmaceuticals, Inc. |
Modified caspase polypeptides and uses thereof
|
SG11201506974XA
(en)
|
2013-03-14 |
2015-10-29 |
Bellicum Pharmaceuticals Inc |
Methods for controlling t cell proliferation
|
CA2903576C
(en)
|
2013-03-15 |
2021-06-08 |
Nai-Kong V. Cheung |
High affinity anti-gd2 antibodies
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
EP3569253A1
(de)
|
2013-06-05 |
2019-11-20 |
Bellicum Pharmaceuticals, Inc. |
Verfahren zur induktion von partieller apoptose mithilfe von caspasepolypeptiden
|
EP3663405A1
(de)
|
2013-06-11 |
2020-06-10 |
Takara Bio USA, Inc. |
Proteinangereicherte mikrovesikel und verfahren zur herstellung und verwendung davon
|
CA2956667A1
(en)
*
|
2013-07-29 |
2015-02-05 |
Bluebird Bio, Inc. |
Multipartite signaling proteins and uses thereof
|
EP3049521B1
(de)
|
2013-09-25 |
2019-03-06 |
Cornell University |
Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
|
EP3087101A4
(de)
|
2013-12-20 |
2017-12-06 |
Novartis AG |
Regulierbarer chimärer antigenrezeptor
|
CN111849912B
(zh)
|
2014-02-14 |
2024-03-15 |
贝里坤制药股份有限公司 |
用诱导型嵌合多肽活化t细胞的方法
|
WO2015127242A1
(en)
*
|
2014-02-21 |
2015-08-27 |
President And Fellows Of Harvard College |
De novo design of allosteric proteins
|
CA2955386A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
AU2015312117A1
(en)
|
2014-09-02 |
2017-03-02 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
|
ES2891332T3
(es)
|
2014-09-17 |
2022-01-27 |
Novartis Ag |
Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
|
AU2015341481C1
(en)
|
2014-11-03 |
2021-09-16 |
ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) |
T cell receptors directed against Bob1 and uses thereof
|
EP3262166A4
(de)
|
2015-02-24 |
2018-08-15 |
The Regents of The University of California |
Durch bindung ausgelöste, transkriptionelle schaltungen und verfahren zur verwendung davon
|
CN107667120B
(zh)
|
2015-03-17 |
2022-03-08 |
纪念斯隆-凯特林癌症中心 |
抗muc16抗体及其应用
|
US10441644B2
(en)
|
2015-05-05 |
2019-10-15 |
The Regents Of The University Of California |
H3.3 CTL peptides and uses thereof
|
CA2985081A1
(en)
|
2015-05-13 |
2016-12-15 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-influenza antibodies and methods of use thereof
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
KR20180096788A
(ko)
|
2016-01-08 |
2018-08-29 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
조건적 활성 이종이량체 폴리펩티드 및 이의 사용 방법
|
CA3019426A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
WO2018014039A1
(en)
|
2016-07-15 |
2018-01-18 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors (cars) specific for muc1 and methods for their use
|
BR112019000683A2
(pt)
|
2016-07-15 |
2019-04-24 |
Poseida Therapeutics Inc |
receptores de antígeno quiméricos e métodos para uso
|
WO2018111834A1
(en)
|
2016-12-13 |
2018-06-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
|
EP3574012A1
(de)
|
2017-01-27 |
2019-12-04 |
Memorial Sloan Kettering Cancer Center |
Bispezifische her2- und cd3-bindende moleküle
|
JP2020506916A
(ja)
|
2017-01-30 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性乾癬性関節炎の治療のための抗tnf抗体、組成物、及び方法
|
KR20190115042A
(ko)
|
2017-02-07 |
2019-10-10 |
얀센 바이오테크 인코포레이티드 |
활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
JP2020510430A
(ja)
|
2017-02-28 |
2020-04-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Aavベクターに基づくインフルエンザワクチン
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
FI3589730T3
(fi)
|
2017-02-28 |
2024-02-22 |
Univ Pennsylvania |
Kladin f adenoassosioitunut virus (aav) -vektori ja sen käyttötapoja
|
CN107488636A
(zh)
*
|
2017-09-30 |
2017-12-19 |
山东兴瑞生物科技有限公司 |
一种携带分子开关的抗her2嵌合抗原受体修饰的免疫细胞及其应用
|
MX2020003888A
(es)
|
2017-10-18 |
2020-11-06 |
Regenxbio Inc |
Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
|
EP3697449A1
(de)
|
2017-10-18 |
2020-08-26 |
REGENXBIO Inc. |
Behandlung von augenkrankheiten und metastasierendem dickdarmkrebs mit menschlicher post-translational modifizierter vegf-falle
|
CN111565737A
(zh)
|
2017-12-14 |
2020-08-21 |
蓝鸟生物公司 |
Daric白细胞介素受体
|
US20210139557A1
(en)
|
2017-12-20 |
2021-05-13 |
Poseida Therapeutics, Inc. |
Vcar compositions and methods for use
|
JP2021523138A
(ja)
|
2018-05-11 |
2021-09-02 |
ヤンセン バイオテツク,インコーポレーテツド |
Il−23抗体を使用してうつを治療する方法
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
JP2022513507A
(ja)
|
2018-12-20 |
2022-02-08 |
ポセイダ セラピューティクス,インコーポレイティド |
ナノトランスポゾン組成物および使用方法
|
US20220153830A1
(en)
|
2019-03-14 |
2022-05-19 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-TNF Antibody Compositions
|
CA3133388A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
EP3938391A1
(de)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Verfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
|
CN113966236A
(zh)
|
2019-04-03 |
2022-01-21 |
再生生物股份有限公司 |
眼睛病状的基因疗法
|
EP3959323A1
(de)
|
2019-04-24 |
2022-03-02 |
REGENXBIO Inc. |
Vollständig menschliche posttranslational modifizierte antikörpertherapeutika
|
EP3972690A4
(de)
|
2019-05-23 |
2023-07-05 |
Janssen Biotech, Inc. |
Verfahren zur behandlung einer entzündlichen darmerkrankung mit einer kombinationstherapie von antikörpern gegen il-23 und tnf-alpha
|
EP3976648A1
(de)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech, Inc. |
Anti-tnf-antikörperzusammensetzungen und verfahren zur behandlung von aktiver psoriasis-arthritis
|
AU2020288404A1
(en)
|
2019-06-03 |
2022-02-03 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
MX2022002366A
(es)
|
2019-08-26 |
2022-07-19 |
Regenxbio Inc |
Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente.
|
JP2022547866A
(ja)
|
2019-09-05 |
2022-11-16 |
ポセイダ セラピューティクス,インコーポレイティド |
同種異系細胞組成物と使用方法
|
MX2022004146A
(es)
|
2019-10-07 |
2022-09-19 |
Regenxbio Inc |
Composición farmacéutica de vector de virus adenoasociado y métodos.
|
WO2021127505A1
(en)
|
2019-12-20 |
2021-06-24 |
Poseida Therapeutics, Inc. |
Anti-muc1 compositions and methods of use
|
AU2021230361A1
(en)
|
2020-03-04 |
2022-09-08 |
Poseida Therapeutics, Inc. |
Compositions and methods for the treatment of Metabolic Liver Disorders
|
WO2021183795A1
(en)
|
2020-03-11 |
2021-09-16 |
Poseida Therapeutics, Inc. |
Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
|
CN115996747A
(zh)
|
2020-04-14 |
2023-04-21 |
波赛达治疗公司 |
用于治疗癌症的组合物和方法
|
WO2021214588A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating coronavirus infections
|
WO2021214587A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating viral infections
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
EP4213890A1
(de)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vektorisierte lanadlumab und verabreichung davon
|
WO2022076582A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Gene therapy for ocular manifestations of cln2 disease
|
EP4236999A1
(de)
|
2020-10-28 |
2023-09-06 |
RegenxBio Inc. |
Vektorisierte anti-tnf-alfa-antikörper für augenindikationen
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
MX2023004843A
(es)
|
2020-10-29 |
2023-05-10 |
Regenxbio Inc |
Antagonistas de tnf-alfa con vectorizacion para indicaciones oculares.
|
WO2022094255A2
(en)
|
2020-10-29 |
2022-05-05 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
CN116670152A
(zh)
|
2020-12-01 |
2023-08-29 |
宾夕法尼亚州大学信托人 |
具有组织特异性靶向基序的新型组合物和含有其的组合物
|
EP4298205A1
(de)
|
2021-02-23 |
2024-01-03 |
Poseida Therapeutics, Inc. |
Genetisch modifizierte induzierte pluripotente stammzellen und verfahren zur verwendung davon
|
EP4301863A1
(de)
|
2021-03-04 |
2024-01-10 |
Poseida Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von hämophilie
|
BR112023021971A2
(pt)
|
2021-04-23 |
2024-02-20 |
Univ Pennsylvania |
Composições com motivos de direcionamento específicos do cérebro e composições contendo os mesmos
|
AU2022306144A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
WO2023281463A1
(en)
|
2021-07-09 |
2023-01-12 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
TW202325845A
(zh)
|
2021-10-02 |
2023-07-01 |
賓州大學委員會 |
新穎aav衣殼及含其之組成物
|
CA3233506A1
(en)
|
2021-10-04 |
2023-04-13 |
Joseph S. LUCAS |
Transposon compositions and methods of use thereof
|
WO2023147304A1
(en)
|
2022-01-25 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
WO2023164573A1
(en)
|
2022-02-23 |
2023-08-31 |
Poseida Therapeutics, Inc. |
Genetically modified cells and methods of use thereof
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
TW202400803A
(zh)
|
2022-05-03 |
2024-01-01 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
WO2024036273A1
(en)
|
2022-08-11 |
2024-02-15 |
Poseida Therapeutics, Inc. |
Chimeric cd8-alpha co-receptor compositions and methods of use
|
WO2024073669A1
(en)
|
2022-09-30 |
2024-04-04 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|